Invitrogen Renews, Expands License and Supply Agreement with Luminex

Invitrogen Corporation (NASDAQ: IVGN), a provider of essential life science technologies for research, production and diagnostics, and Luminex Corporation (NASDAQ: LMNX), today announced the renewal and expansion of Invitrogen's license and supply agreement for Luminex's multiplexed analyte detection technology and systems. The new agreement extends the lifetime of the license and provides Invitrogen with access to Luminex's next-generation multiplex detection platforms.

xMAP(R) Technology and Luminex instrument platforms use proprietary microspheres - micron-sized beads - encoded with combinations of spectrally distinct fluorescent dyes to rapidly and reproducibly determine the relative concentrations of many different proteins or peptides at the same time in the same sample.

Invitrogen offers more than 200 assays based on xMAP Technology, comprising the most comprehensive multiplex protein assay menu in life sciences for cellular pathway and disease analysis. Invitrogen also has a large number of new multiplexed assays in its product development pipeline to expand the number of targets accessible to scientists. The company will offer custom assay development services using the next-generation platform that complement its existing service of rapid, affordable multiplex assay development on the original Luminex platform.

"We are pleased with this new agreement and committed to our relationship with Luminex," said Kip Miller, Invitrogen's Senior Vice President, BioDiscovery. "It is another step in our strategy of building on our position as the leading cell biology reagent provider to offer our customers integrated systems and solutions."

"We believe the extension of the agreement is beneficial for both companies, as Luminex has quickly become a standard in the industry for multiplexing and Invitrogen has the ability to offer the broadest array of content for this important platform," added August Sick, Invitrogen Vice President and General Manager, Cellular Analysis Business Unit. "The assays we will develop on Luminex's next-generation platform will further accelerate drug discovery and cellular analysis."

"Luminex is pleased to extend and expand our relationship with Invitrogen," said Doug Bryant, executive vice president and chief operating officer of Luminex. "Partnering with innovative leaders such as Invitrogen is a key element in our business strategy. We look forward to a valuable, long-term collaboration with Invitrogen."